Navigation Links
Oncothyreon announces closing of $11.1 million registered direct financing
Date:5/27/2009

SEATTLE, May 27 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) announced today that it closed its previously announced sale of 3,878,993 shares of its common stock and warrants to purchase 2,909,244 shares of its common stock for gross proceeds of approximately $11.1 million on May 26, 2009. Oncothyreon sold the shares and warrants for $2.85 per unit (each unit consisting of one share and a warrant to purchase 0.75 shares of common stock). The exercise price of the warrants is $3.92 per share. The warrants will be exercisable at any time on or after the six-month anniversary and on or prior to the fifth anniversary of the closing of the transaction on May 26, 2009. Oncothyreon plans to use the proceeds from this financing for general corporate purposes. Boenning & Scattergood, Inc. acted as exclusive placement agent in the transaction.

A registration statement relating to these securities (File # 333-149837) has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor, shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any offer of these securities will be solely by means of a prospectus included in the registration statement and any prospectus supplement that may be issued with respect to such offering. Copies of the final prospectus, including the prospectus supplement, can be obtained at the Securities and Exchange Commission's website, www.sec.gov, from Oncothyreon at its Seattle, Washington address below or Boenning & Scattergood, Inc. by calling 1-800-883-1212.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing
2. Oncothyreons PX-866 is effective in preclinical model of pulmonary fibrosis
3. Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
4. Oncothyreon reports first quarter 2009 financial results
5. Oncothyreon regains compliance with NASDAQ listing requirements
6. Oncothyreon to present at Invest Northwest 2009
7. Oncothyreon reports full year and fourth quarter 2008 financial results
8. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
9. Oncothyreon to present at BIO CEO & Investor Conference 2009
10. Oncothyreon reports third quarter 2008 financial results
11. Oncothyreon to present at Rodman & Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... Dr. Greg Leyer, Chief Scientific Officer of UAS ... His presentation is at 12:10pm in the Probiotics Resource Center, Mandalay Bay Expo Hall. ... and discuss how probiotics have shown impressive data in areas outside the gut including ...
(Date:9/21/2017)... New Jersey (PRWEB) , ... September 21, 2017 ... ... highly-regulated pharmaceutical and clinical research sector professionals, has announced the addition of 5 ... Part 11 training - Compliance with Regulation 21 CFR Part 11 on ...
(Date:9/20/2017)... ... September 20, 2017 , ... The award-winning ... Services (Koch) to feature new innovations aimed at helping farmers solve the problem ... American Farmer airs Tuesdays at 8:30aET on RFD-TV. Check your local listings for ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... pathology, and Huron Digital Pathology , a provider of whole slide imaging ... Pathology Visions conference . The workshop, entitled “Successfully Deploying a Best-in-Class Strategy for ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/28/2017)... , March 28, 2017 ... Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video ... and Region - Global Forecast to 2022", published by ... in 2016 and is projected to reach USD 75.64 ... 2017 and 2022. The base year considered for the ...
Breaking Biology News(10 mins):